Short answer · Medically reviewed summary · Last updated: 2026-04-07
Takayasus Arteritis was first described in 1908 by Japanese ophthalmologist Mikito Takayasu, who observed unique retinal vascular changes in a 21-year-old woman during a meeting of the Japan Ophthalmological Society. From Ocular Observation to Systemic Understanding While Dr. Takayasu initially identified the condition through the distinctive "wreath-like" arteriovenous anastomoses in the eyes, it was not until later that colleagues Onishi and Kagoshima noted the absence of the patient’s radial pulse.
4 people with Takayasus Arteritis have shared their first-person experience on this question at DiseaseMaps.
Takayasus Arteritis was first described in 1908 by Japanese ophthalmologist Mikito Takayasu, who observed unique retinal vascular changes in a 21-year-old woman during a meeting of the Japan Ophthalmological Society.
While Dr. Takayasu initially identified the condition through the distinctive "wreath-like" arteriovenous anastomoses in the eyes, it was not until later that colleagues Onishi and Kagoshima noted the absence of the patient’s radial pulse. This realization shifted the medical community's focus from a localized ocular issue to a systemic condition involving the large arteries, specifically the aorta and its primary branches. Initially, Takayasus Arteritis was frequently mislabeled as "pulseless disease," a term that underscored the severe arterial narrowing but failed to capture the underlying inflammatory nature of the illness.
The historical understanding of Takayasus Arteritis has evolved from observation to sophisticated immunology. For much of the 20th century, treatment was largely supportive or limited to surgical intervention for arterial stenosis. The introduction of high-dose corticosteroids in the mid-20th century marked a major milestone, providing a way to modulate the inflammatory response. Today, the management of Takayasus Arteritis has transitioned toward the use of steroid-sparing agents and biologic therapies, such as TNF-alpha inhibitors and IL-6 receptor antagonists, which target specific pathways of inflammation.
Technological leaps have revolutionized how we diagnose Takayasus Arteritis. Where clinicians once relied solely on physical exams and invasive angiography, we now utilize PET-CT scans and high-resolution MRI to detect vessel wall inflammation before permanent damage occurs. Furthermore, the rise of global patient advocacy groups has transformed the patient experience. By connecting individuals through platforms like DiseaseMaps, those living with Takayasus Arteritis have moved from isolated experiences to a collective voice that drives awareness, accelerates research, and fosters emotional resilience.
Medical Disclaimer: This information is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.